TII
The Secure Systems Research Centre (SSRC) at Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced the launch of its first Reduced Instruction Set Computer (RISC-V) based drone flight controller that leverages the Centre’s own secure PX4 stack. The flight marks a milestone in SSRC’s path to making RISC-V based UAV systems a reality through this successful testing and validation of the RISC-V + the secure PX4 stack system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005440/en/
Earlier this year, the Centre became a strategic member of RISC-V International, a non-profit organisation controlled by its members, which directs the future development and drives the adoption of RISC-V free and open Instruction Set Architecture (ISA). SSRC is focused on building an RISC-V based secure flight computer system. Today’s milestone is a major signpost on this path, with the Centre using a commercially available RISC-V development platform to port the DroneCode PX4 open source software to RISC-V.
Dr. Ray O. Johnson, CEO of TII, said: “RISC-V’s ISA is revolutionising the world of computing systems, and TII is proud to build this capability into our growing collection of breakthrough solutions that are future-proofing our world – one step at a time. We are seeing the use cases for drones and similar autonomous systems now spanning multiple sectors from e-commerce to healthcare and communication to security. This achievement will further strengthen our credibility as a global research centre at the forefront of cutting-edge technology that is working to shape an enabled and more secure world.”
Dr. Shreekant (Ticky) Thakkar, Chief Researcher, SSRC, said: “We are putting TII on the world map as leaders in pioneering Zero Trust Drone System research through this effort. The DroneCode community is the leading open-source community of PX4 Autopilot and fight controller hardware code and specification, respectively. A significant part of the work in realising this project required the porting of NuttX real-time OS and PX4 flight controller software to the RISC-V platform. SSRC has already included some of the planned security improvements into its existing PX4 software stack, and we will continue to develop this software and contribute the modifications back to open source.”
He added: “Through this milestone, we intend to highlight our regional expertise in the research and development of security for Drone and Autonomous Systems, an area that is set to have an outsized impact in shaping the Smart Cities of the future - making them safer and also significantly accelerating the opportunities for new services.”
As a follow-up, SSRC will continue to improve the security and resilience of the open source PX4 flight control software stack and NuttX real-time OS in collaboration with open source community. Furthermore, the Centre has presented a roadmap that includes improving memory protection of NuttX OS and PX4, protecting data on the removable media and utilising commercially available Root-of-Trust components.
Jukka Laitinen, Drone Software Lead Engineer and Architect at the SSRC in TII and Technical Lead for Dronecode Security Special Interest Group also presented a talk on making the current drone platform better, more secure, and resilient at the PX4 Autopilot Development Summit in September 2021.
SSRC is on track to achieving the first TII custom flight controller hardware, with the initial prototypes of this hardware, using a commercial off-the-shelf RISC-V SoC, expected by Q1 2022. This will enable researchers and industry to replace existing commercial flight controllers with a TII secure flight controller.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005440/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press release
A R$490 million investment expands the supply of raw material used in the production of absorbent items Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
